Glonghui December 1: Some investors asked Shuanglu Pharmaceutical (002038.SZ) on the investor interactive platform, “Is the company's GLP-1 formulation expected to be registered this year?” The company replied that the Japanese drug has now completed phase III clinical trials and is in the clinical data collation stage. Currently, it has completed follow-up of all phase III subjects, and it is expected that registration applications will be submitted next year.
双鹭药业(002038.SZ)：日制剂目前已完成Ⅲ期所有受试者随访，预计明年提交注册申请
Shuanglu Pharmaceutical (002038.SZ): Nippon Pharmaceutical has now completed phase III follow-up of all test subjects, and is expected to submit registration applications next year
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.